RE:RE:RE:New Press Release - Theratechnologies Announces Operational Update No they can't and Paul should voluntarily agree to a pay cut. Since they said after part3 completion any potential future clinical research will be funded by partners I suspect some of those 25 employees are preclinical/clinical managers working on the oncology platform. If correct not having in house expertise in my opinion doesn't put them in a good position negotiating with partners.
juniper88 wrote: palinc2000 wrote: Why now?and not before?
Does anyone else find it ironic that the first year's savings will be $2 million USD, which I believe is the same as Paul's salary during that time?
I am sure Paul is a very compentent CEO and all, but can this tiny company reall afford him?